BNET Industries

Titan Pharmaceuticals Inc.

(TTNP) is in the Pharma Industry

Market Cap:$372.2K

Last Fiscal Year Sales:$24.0K

Public
US

Dow Jones Description

We are a biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system (CNS) disorders. Our product development programs focus primarily on large pharmaceutical markets with significant unmet medical needs and commercial potential. Our resources are focused primarily on the development of Probuphine for the treatment of opioid addiction. On July 28, 2008, we issued a press release announcing positive, statistically significant results from our randomized, double-blind, placebo controlled, multi-center Phase III clinical trial of Probuphine for the treatment of opioid addiction. Probuphine also has the potential to provide treatment for chronic pain, and hope to evaluate this application in a proof of concept clinical study if we are able in the very near term to obtain a corporate partner or otherwise raise the funds necessary to continue this program. See Liquidity and Capital Resources below. On July 2, 2008, we issued a press release announcing the results of the initial analyses of data from a Phase IIb clinical study of Spheramine in Parkinsons disease conducted by our licensee, Bayer Schering Pharma AG, Germany (Bayer Schering). Spheramine did not meet the Phase IIb clinical studys primary or key secondary endpoints, with no significant differences detected between the Spheramine and sham surgery arms of the study. ...

Number of Employees 30

Contact Information

400 Oyster Point Blvd Ste 505

South San Francisco, California 94080-1921

(650) 244-4990

Peer Companies

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

Company News

Recent Events

Novartis Pharma Inks Pact with Vanda Pharmaceuticals for Commercialization of Fanapt in the U.S. and...

10/14/09 - Joint Venture / Alliance - View Story
Novartis Pharma AG NVS JOBS Acquires Exclusive Rights From Vanda Pharmaceuticals, Inc. VNDA for Commercialization...

10/13/09 - Joint Venture / Alliance - View Story

News & Analysis

Filter by

Sort Type
Content Type
Related Tags

titan pharmaceuticals inc. - All News and Analysis

Titan Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript

Seeking Alpha - 2008-11-11

Question-and-Answer Session Operator Thank you. Operator instructions. Marc Rubin Okay, if there are no questions, I want to thank you operator and thank you all for joining us for today’s call. We look forward to continuing to provide you with Titan updates and discussing our progress with you...

Tags: Call Transcript, Earnings, Transcript, Titan Pharmaceuticals Inc., Financial Accounting, Internet, Finance, Seeking Alpha
Titan Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript

Seeking Alpha - 2008-09-23

Question-and-Answer Session Operator Operator instructions Our first question comes from the line of Ram Selvaraju from Rodman & Renshaw. Please proceed. Ram Selvaraju – Rodman & Renshaw Hi, thanks very much for taking my question. First of all, Marc, if you could just reiterate the P-values...

Tags: Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Announces Spheramine® Presentations at 12th International Congress of Parkinson's Disease and Movement Disorders

- 2008-06-24

Five-Year Update of Pilot Study Shows Spheramine Reduces Severity and Frequency of Parkinson's Symptoms While Also Improving Health-Related Quality of Life CHICAGO & SOUTH SAN FRANCISCO -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that Spheramine[R], the company's novel cell-based therapy being developed in collaboration with Bayer Schering Pharma AG...

Tags: cell, Company, efficacy, Parkinson, patient, Titan Pharmaceuticals Inc., U.S. Congress
Titan Pharmaceuticals, Inc. to Acquire Commercial Rights to Pivanex

- 1997-07-18

SOUTH SAN FRANCISCO, CA--BW HealthWire--July 18, 1997--TITAN PHARMACEUTICALS, INC. (NASDAQ: TTNP, TTNPU, and TTNPW) announced today that it has entered into an exclusive worldwide license agreement to acquire all commercial rights to PivanexTM, an anti-cancer agent currently in Phase I testing, from its affiliate Ansan Pharmaceuticals, Inc. (Nasdaq ANSN,...

Tags: agent, equity, FINANCE, Investment, merger, Nasdaq Stock Market Inc., Titan Pharmaceuticals Inc.
Titan Pharmaceuticals, Inc. Announces Issuance of US Patent on Polymeric System for Controlled Drug Delivery to the CNS

- 1997-05-08

SOUTH SAN FRANCISCO, CA--BW HealthWire--MAY 8, 1997--TITAN PHARMACEUTICALS, INC. (NASDAQ: TTNP, TTNPU, and TTNPW) today announced the issuance of US patent 5,601,835, licensed exclusively to its major owned subsidiary, ProNeura, Inc. from the Massachusetts Institute of Technology ("MIT"). This patent covers a unique polymeric system applicable to the direct...

Tags: issuance, Massachusetts Institute of Technology, patent, Titan Pharmaceuticals Inc.

Titan Pharmaceuticals Licenses Iloperidone From Hoechst Marion Roussel

- 1997-01-09

SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Jan. 9, 1997-- Titan Pharmaceuticals Inc. (NASDAQ NM: TTNP, TTNPU AND TTNPW), today announced that it has signed an agreement with Hoechst Marion Roussel, Inc. for an exclusive worldwide license to the antipsychotic agent, Iloperidone. Iloperidone, which is expected to enter Phase III...

Tags: agent, agreement, Nasdaq Stock Market Inc., Titan Pharmaceuticals Inc.
Titan Pharmaceuticals, Inc. announces appointment of Robert E. Farrell as chief financial officer

- 1996-09-19

SOUTH SAN FRANCISCO--BUSINESS WIRE--Sept. 19, 1996--TITAN PHARMACEUTICALS, INC. (NASDAQ: TTNP, TTNPU, and TTNPW) today announced that Robert E. Farrell has joined the company as Executive Vice President and Chief Financial Officer.Mr. Farrell has extensive experience as a financial executive and has held a variety of management positions throughout his career....

Tags: Business Wire, Nasdaq Stock Market Inc., Titan Pharmaceuticals Inc.
Titan Pharmaceuticals completes $16,000,000 private placement

- 1996-08-02

SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Aug. 2, 1996--Titan Pharmaceuticals, Inc. (NASDAQ NM: TTNP, TTNPU AND TTNPW), announced today that it completed the sale of units composed of an aggregate of 1,536,000 shares of its Common Stock, par value $.001 per share (the "Shares"), and 1,536,000 redeemable Class A Warrants of Titan...

Tags: Business Wire, Company, Titan Pharmaceuticals Inc.
Titan Pharmaceuticals, Inc. elects Ernst-Gunter Afting, Ph.D. to board of directors

- 1996-05-31

SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--May 31, 1996-- TITAN PHARMACEUTICALS, INC. (NASDAQ NM: TTNP, TTNPU AND TTNPW) today announced that Ernst-Gunter Afting, Ph.D. will join Titan's board of directors, effective immediately.Dr. Afting is a ten-year veteran of international pharmaceutical corporation Hoechst Group, most recently serving as President and CEO...

Tags: board, Dr., Nasdaq Stock Market Inc., Titan Pharmaceuticals Inc.

1

page 1 of 1

Those who viewed this also viewed...

Roche/Genentech Exodus No Longer Voluntary

Click Here

TTNP $2.20 -0.08 (-3.51% )

Intraday

|

3 Month

|

6 Month

|

1 Year

Average Volume	240,902
Shares Outstanding	58.29M
Market Cap	128.2M
Year High	2.48
Year Low	0.02
Earnings Per Share	N/A
P/E Ratio	-
Dividend	N/A
Yield	N/A

Industry Transcripts by Seeking Alpha

Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN

Glass Door

Pharma Industry Companies

Company	Employer Rating
Johnson & Johnson	3.3
Merck	3.2
Pfizer	3.0
Novartis	2.8
Abbott Labs	3.2

IndustryTop Rated

Your Work The 7 Interview Questions You Must Ask

The 7 Interview Questions You Must Ask

Forget 'What are your strengths and weaknesses?' If you want to get the real dope on prospective employees, ask job candidates these seven questions.
Your Industry Why Goldman's Apology Was a Waste of Time and Money

Why Goldman's Apology Was a Waste of Time and Money

Goldman Sachs (GS) apologized for its role in the financial crisis this week and announced it would invest $500 million in small businesses as a mea culpa. But corporate reputation expert Eric Dezenhall believes the move may be an expensive and pointless kabuki show for the unwashed masses who don't understand how the firm really works.
Your Money Dumbest Things You Do With Your Money

Dumbest Things You Do With Your Money

Even smart people make financial moves that are downright illogical. Emotions and superstitions have a sneaky way of keeping you from rational financial decisions. But dumb choices can have serious, real-world consequences. Here are some of the biggest blunders we all make, plus tips from the experts on how to keep cool.